Evolus Expands with Estyme®: EU Certification for Injectable Hyaluronic Acid Gels

Evolus Expands Market Reach with New Injectable Hyaluronic Acid Gels

Evolus, Inc., a performance beauty company recognized for its focus on aesthetic consumer brands, recently achieves a major milestone by securing EU Medical Device Regulation (MDR) certification for its injectable hyaluronic acid gels branded as Estyme®. This certification not only allows Evolus to enter the European dermal filler market but also represents a strategic expansion of its addressable market beyond the United States. With the European dermal filler market estimated at $1.8 billion, this move positions Evolus to tap into a lucrative segment while reinforcing its commitment to quality and safety in its offerings.

The CE Mark certification, obtained through the stringent MDR process, underscores the rigorous standards Evolus meets to ensure the safety, efficacy, and quality of its medical devices in Europe. As part of its entry strategy, Evolus plans to roll out Estyme® through a limited experience program in collaboration with select physician partners. This initiative is designed to gather valuable insights that will inform a broader launch anticipated in the latter half of 2025. David Moatazedi, President and CEO of Evolus, emphasizes that this regulatory achievement reflects the company's dedication to high-quality products that stand up to rigorous standards, which is essential in the highly competitive aesthetic market.

Dr. Rui Avelar, Chief Medical Officer and Head of R&D at Evolus, notes that Estyme® signifies a notable innovation in the aesthetic space. The product features proprietary cold technology and advanced cross-linking techniques that enhance the natural hyaluronic acid chain, setting it apart from existing competitors. As Evolus prepares for the anticipated U.S. launch of its injectable HA gels under the Evolysse™ brand, expected to commence in 2025, the company is firmly establishing itself as a forward-thinking leader in the aesthetic neurotoxin market. This dual strategy of expanding into Europe while preparing for the U.S. market allows Evolus to cater to the next generation of beauty consumers, aligning with its mission to become a top global multi-product aesthetic company.

In addition to its regulatory achievements, Evolus continues to innovate through its customer-centric model and advanced digital platform. These initiatives enhance consumer engagement and streamline the aesthetic experience, positioning the company favorably for future growth in a rapidly evolving industry landscape. As Evolus moves forward, its focus on high-quality product development and strategic market expansion remains central to its vision of redefining beauty standards globally.